阿卡迪亞 ACAD 深 滬
已收盤 02-06 16:00:00 美东时间
23.56
+0.100
+0.43%
華盛通- 最 高24.04
- 今 開24.04
- 成交量 235.59万股
- 最 低 23.37
- 昨 收 23.46
- 總市值 39.86亿
- 52周最高 28.35
- 市盈率 靜 17.31
- 換手率 1.39%
- 52周最低 13.40
- 委 比 -96.90%
- 總股本 1.69亿
- 歷史最高 58.72
- 量 比 1.68
- 振 幅 2.86%
- 歷史最低 0.90
- 每 手 1
- 風險率 3.70%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅213.87%！Wave Life Sciences获Canaccord Genuity升目标价至43美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Wave Life Sciences Ltd."买入"评级，目标价从40美元升至43美元；花旗：维持Palantir Technologies"买入"评级，目标价从235美元升至260美元
02-04 12:15
EU Panel Rejects Acadia Pharmaceuticals Rett Syndrome Drug
EU drug advisers issued a negative vote on Acadia's Rett syndrome treatment trofinetide. The company plans to seek a re-examination after the opinion is formally adopted.
02-04 01:44
ACADIA Pharmaceuticals Announces That The Co, Was Informed By The CHMP Of The EMA Of A Negative Trend Vote On Its Marketing Authorization Application For Trofinetide For The Treatment Of Rett Syndrome
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) today announced that the Company was informed by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) of a negative trend vote on its
02-03 05:09
ACADIA Pharmaceuticals Clarifies Form 8-K Disclosure Treatment
ACADIA Pharmaceuticals ( ($ACAD) ) has issued an announcement. In a recent regu...
01-14 05:17
美股大行评级 | 拼多多、小鹏获Freedom上调目标价；多家大行首予Wealthfront"超配"评级，目标价最高23美元
今日重点评级关注：HC Wainwright & Co.：维持MetaVia Inc."买入"评级，目标价从12美元升至40美元；Canaccord Genuity：维持GH Research"买入"评级，目标价从35美元升至39美元
01-07 17:25
UBS Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $40
UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $35 to $40.
01-07 01:21
美国FDA扩大血液病药物适应症获批，阿卡迪亚制药股价应声大涨
美国食品药品监督管理局（FDA）批准阿卡迪亚制药一款血液病治疗药物扩大适应症范围，受该利好消息影响，阿卡迪亚制药股价在周三美股盘前交易中暴涨近 12%。 ...
2025-12-24 21:42
美股大行评级 | 潜在涨幅113%！麦格理首予小马智行“跑赢大市"评级目标价29美元；Roth Capital下调好市多至"卖出"，目标价从906美元降至769美元
今日重点评级关注：HC Wainwright & Co.：维持BioCryst Pharma"买入"评级，目标价从30美元升至32美元；TD Cowen：上调Milestone Pharmaceuticals评级至"买入"，目标价8美元
2025-12-16 09:36
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
2025-12-12 10:24
Stifel Maintains Hold on ACADIA Pharmaceuticals, Raises Price Target to $25
Stifel analyst Paul Matteis maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Hold and raises the price target from $24 to $25.
2025-12-11 21:15
